Pathomechanisms Underlying X-Adrenoleukodystrophy: A Three-Hit Hypothesis

被引:101
作者
Singh, Inderjit [1 ]
Pujol, Aurora [2 ,3 ,4 ,5 ]
机构
[1] Med Univ S Carolina, Dept Pediat, Darby Children Res Inst, Charleston, SC 29425 USA
[2] Hosp Llobregat, Neurometab Dis Lab, Inst Invest Biomed Bellvitge IDIBELL, Barcelona, Spain
[3] Hosp Llobregat, Inst Neuropathol, Inst Invest Biomed Bellvitge IDIBELL, Barcelona, Spain
[4] ICREA, Barcelona, Spain
[5] Ctr Biomed Res Rare Dis CIBERER, Barcelona, Spain
关键词
axonal degeneration; demyelination; neuroinflammation; oxidative stress; peroxisomes; plasmalogens; VLCFA; X-adrenoleukodystrophy; CHAIN FATTY-ACIDS; CENTRAL-NERVOUS-SYSTEM; PEROXISOMAL ABCD2 TRANSPORTER; RAT-LIVER PEROXISOMES; C6; GLIAL-CELLS; LINKED ADRENOLEUKODYSTROPHY; LONG-CHAIN; OXIDATIVE STRESS; NITRIC-OXIDE; MOUSE MODEL;
D O I
10.1111/j.1750-3639.2010.00392.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
X-adrenoleukodystrophy (X-ALD) is a complex disease where inactivation of ABCD1 gene results in clinically diverse phenotypes, the fatal disorder of cerebral ALD (cALD) or a milder disorder of adrenomyeloneuropathy (AMN). Loss of ABCD1 function results in defective beta oxidation of very long chain fatty acids (VLCFA) resulting in excessive accumulation of VLCFA, the biochemical "hall mark" of X-ALD. At present, the ABCD1-mediated mechanisms that determine the different phenotype of X-ALD are not well understood. The studies reviewed here suggest for a "three-hit hypothesis" for neuropathology of cALD. An improved understanding of the molecular mechanisms associated with these three phases of cALD disease should facilitate the development of effective pharmacological therapeutics for X-ALD.
引用
收藏
页码:838 / 844
页数:7
相关论文
共 67 条
  • [31] BRAIN GANGLIOSIDES IN ADRENOLEUKODYSTROPHY
    IGARASHI, M
    BELCHIS, D
    SUZUKI, K
    [J]. JOURNAL OF NEUROCHEMISTRY, 1976, 27 (01) : 327 - &
  • [32] Axonal loss and neuroinflammation caused by peroxisome-deficient oligodendrocytes
    Kassmann, Celia M.
    Lappe-Siefke, Corinna
    Baes, Myriam
    Bruegger, Britta
    Mildner, Alexander
    Werner, Hauke B.
    Natt, Oliver
    Michaelis, Thomas
    Prinz, Marco
    Frahm, Jens
    Nave, Klaus-Armin
    [J]. NATURE GENETICS, 2007, 39 (08) : 969 - 976
  • [33] Endotoxin-induced alterations of lipid and fatty acid compositions in rat liver peroxisomes
    Khan, M
    Contreras, M
    Singh, I
    [J]. JOURNAL OF ENDOTOXIN RESEARCH, 2000, 6 (01): : 41 - 50
  • [34] Khan M, 1998, J NEUROCHEM, V71, P78
  • [35] Plasmalogen deficiency in cerebral adrenoleukodystrophy and its modulation by lovastatin
    Khan, Mushfiquddin
    Singh, Jaspreet
    Singh, Inderjit
    [J]. JOURNAL OF NEUROCHEMISTRY, 2008, 106 (04) : 1766 - 1779
  • [36] Very long-chain fatty acid accumulation causes lipotoxic response via 5-lipoxygenase in cerebral adrenoleukodystrophy
    Khan, Mushfiquddin
    Singh, Jaspreet
    Gilg, Anne G.
    Uto, Takuhiro
    Singh, Inderjit
    [J]. JOURNAL OF LIPID RESEARCH, 2010, 51 (07) : 1685 - 1695
  • [37] MEMBRANE MICROVISCOSITY IS INCREASED IN THE ERYTHROCYTES OF PATIENTS WITH ADRENOLEUKODYSTROPHY AND ADRENOMYELONEUROPATHY
    KNAZEK, RA
    RIZZO, WB
    SCHULMAN, JD
    DAVE, JR
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1983, 72 (01) : 245 - 248
  • [38] ABCD2 is abundant in adipose tissue and opposes the accumulation of dietary erucic acid (C22:1) in fat
    Liu, Jingjing
    Sabeva, Nadezhda S.
    Bhatnagar, Saloni
    Li, Xiang-An
    Pujol, Aurora
    Graf, Gregory A.
    [J]. JOURNAL OF LIPID RESEARCH, 2010, 51 (01) : 162 - 168
  • [39] A mouse model for X-linked adrenoleukodystrophy
    Lu, JF
    Lawler, AM
    Watkins, PA
    Powers, JM
    Moser, AB
    Moser, HW
    Smith, KD
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (17) : 9366 - 9371
  • [40] TUMOR-NECROSIS-FACTOR-ALPHA AND X-LINKED ADRENOLEUKODYSTROPHY
    MCGUINNESS, MC
    GRIFFIN, DE
    RAYMOND, GV
    WASHINGTON, CA
    MOSER, HW
    SMITH, KD
    [J]. JOURNAL OF NEUROIMMUNOLOGY, 1995, 61 (02) : 161 - 169